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Abnormal fragile histidine triad transcripts were found in 20–30% of CIN2/3 lesions and 11% of normal cervical biopsies by
RT–PCR. Bi-allelic loss of the fragile histidine triad gene and the loss of fragile histidine triad protein expression detectable by
immunochemical staining with a polyclonal fragile histidine triad speciﬁc antibody was rare. The genomic changes showed no
association with the presence of human papillomavirus types which carry high risk for cervical cancer (high risk human
papillomavirus) as assessed by a type-speciﬁc multiplex PCR. The presence of abnormal fragile histidine triad transcripts in a
subset of CIN2/3 lesions with no high risk human papillomavirus suggests that this could be an independent risk factor
associated with an alternative carcinogenic pathway.
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Cervical cancer is the second most common malignancy in women
worldwide. It is generally accepted that the development of cervical
cancer from precancers (CIN2/3) involves multistep molecular
changes and is therefore a preventable disease if precancers are
detected and treated early.
The major risk factor for CIN2/3 and cancer is infection with
high risk human papillomavirus (HR HPV) types which include
HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV51,
HPV52, HPV56, HPV58, HPV59 and HPV68. One or more of
these virus types have been reported to be present in 90–95% of
CIN2/3 lesions and in nearly all cancers (Lorincz et al, 1992; Bosch
et al, 1995; Walboomers et al, 1996). However, infection with HR
HPV does not invariably lead to the development of high grade
cervical lesions and there is a clear requirement for other co-
factors, presumably to advance the oncogenic process initiated by
HR HPV (zur Hausen, 1999). The effects of co-factors are difﬁcult
to measure objectively because of the dominant effects of HR HPV
infection but tobacco smoking has consistently been associated
with cervical cancer (Szarewski et al, 1996) and has been found
recently to induce genomic instability in head and neck cancers
(Schantz et al, 2000). Other potential co-factors include oral
contraceptive use and other sexually transmitted diseases.
Genomic instability has been found in cervical neoplasia and
commonly involves the short arm of chromosome 3. Results
reported so far are based on small numbers of samples and show
no clear correlation between genomic changes and lesion grades
(Butler et al, 2000; Yoshino et al, 2000). Allelic loss and microsa-
tellite instability were found to occur in lesions with or without
malignant potential in similar proportion (Wistuba et al, 1997;
Chu et al, 1998; Yoshino et al, 1998; Butler et al, 2000; Lin et
al, 2000). Inconsistent results were also obtained in the analysis
of abnormal transcripts encoded by the fragile histidine triad
(FHIT) gene at chromosome 3p14.2. These are also indicative of
genomic instability (Sozzi et al, 1996) but the incidence reported
varies from 30 to 80% in cervical cancer and 0 to 40% in normal
tissue (Greenspan et al, 1997; Chu et al, 1998; Muller et al, 1998;
Su et al, 1998; Yoshino et al, 1998; Nakagawa et al, 1999; Segawa
et al, 1999). In only one study, which involved FHIT protein
staining in 110 parafﬁn sections, was a reduction in FHIT gene
expression observed to correlate with increasing lesion grade
(Birrer et al, 1999). How genetic alterations in chromosome 3p
interact with HR HPV is also not clear (Muller et al, 1998; Butler
et al, 2000). Integration of HPV16 sequences at the FHIT locus
has been described but this does not appear to be site speciﬁc
(Wagatsuma et al, 1990; Wilke et al, 1995). HPV16 sequences
were not present in abnormal FHIT transcripts (Muller et al,
1998) and the presence of HR HPV E6/E7 transcripts and abnor-
mal FHIT transcripts were negatively correlated in cervical cancer
(Segawa et al, 1999).
In this investigation, abnormal FHIT gene expression based
on the detection of abnormal FHIT transcripts or a reduction
of immunohistochemical staining for FHIT protein was studied
in 281 and 114 biopsies respectively, of normal cervix and CIN
lesions. We assessed whether these indicators of genomic
instability at chromosome location 3p14.2 were present at an
early stage, when the oncogenic potential of HR HPV is not
yet fully expressed. The inﬂuence of HR HPV on genomic
instability was also investigated. The potential implications of
abnormal FHIT expression in the pathogenesis of CIN lesions
are discussed.
MATERIALS AND METHODS
Specimens
All specimens were collected in accordance with the guidelines
approved by the Whittington Hospital Trust UK ethics committee.
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Nucleic acid preparations from 281 biopsies of normal cervix and
CIN lesions from a total of 91 women participating in a previous
study of HPV E6 and E7 transcripts (Ho et al, 1994) were used.
Five cancer biopsies from the same study acted as high grade lesion
controls. Routine histology was reviewed by a consultant histo-
pathologist. Nucleic acid extraction was carried out using
guanidinium isothiocyanate at 608C for 10 min to selectively lyse
the epithelium and remove it from the underlying, more resistant,
stromal tissue. After further extraction with hot phenol/chloroform
and digestion with proteinase K (PK, 200 mgm l
71 (Sambrook et
al, 1989)) total nucleic acids were precipitated and stored in
1 ml of ethanol containing 0.3 M sodium acetate (pH 5.2) at
7708C. HPV assays were carried out using 50 ml aliquots which
were centrifuged at 14000 g and 48C for 15 min. The pellet was
re-dissolved in 20 ml of TE (10 mM Tris, 1 mM EDTA, pH 8.0).
Thirteen HR HPV types were assayed by a multiplex type speciﬁc
PCR (mts–PCR) using primers that are completely homologous to
the corresponding HPV genome sequence (Terry et al, 2001). The
3' end of each primer was not homologous to any other region of
any of the 13 genomes. The primers ampliﬁed DNA sequences in
the E6 or E6/E7 genes, the region most likely to be retained after
viral DNA integration.
FHIT transcripts were detected by semi-nested RT–PCR.
Nucleic acids from a 500 ml aliquot in ethanol was pelleted, redis-
solved in TE, digested with RQ1 RNase free DNase I (Amersham
Pharmacia Biotech) at 250 mgm l
71. The RNA was then phenol-
chloroform extracted and re-precipitated with ethanol. FHIT
cDNA was synthesised using a Reverse Transcription System kit
(Promega) and subsequently ampliﬁed for 30 cycles (948C for
30 s, 608C for 1 min, 688C for 2 min) with primers FH203S
(forward) and FH1038 (reverse). The efﬁciency of reverse tran-
scription was monitored using aldolase PCR primers (Chelly et
al, 1988). The PCR product was diluted 1/10 and ampliﬁed in
a semi-nested PCR for a further 30 cycles (cycling conditions as
above) using primers FH203S (forward) and FH904S (reverse).
The FHIT primers were as described by Fong et al (1997) but
with the addition of 5'-leader sequences (nucleotides in lower
case) to allow direct sequencing of the PCR products using avail-
able Cy5 labelled sequencing primers for rubella virus (in
FH203S) or M13 (in FH904S).
FH1038 ÿ 50-AGACAGGGGGAAACCTCAAATC-30
FH203S ÿ 50-ccgaatggcaaaagtCGTAGTGCTATCTACATCCAGACGG-30
FH904S ÿ 50-caggaaacagctatgaccGCTGATTCAGTTCCTCTTGGGG-30
Nucleic acid sequencing was carried out using an ALF-Express
automatic sequencer.
HPV and FHIT protein status
Parafﬁn blocks from corresponding cases used for the FHIT
transcript study were not available due to re-organizations in
the National Health Service. For this analysis 114 biopsies of
normal cervix and CIN lesions from a total of 42 women parti-
cipating in two previous studies of cervical cancer risk factors
(Mansell et al, 1994; Cuzick et al, 1996) were used. Nine cancer
lesions (Cuzick et al, 1996) were included as high grade lesion
controls. Routine histology was reviewed by a consultant histo-
pathologist. Sections (3 mm thick) were mounted on coated
slides (BDH). For HPV genotyping, individual sections were
de-waxed with EZ-DeWax (InnoGenex) according to the
instruction of the manufacturer, scraped from the slide, washed
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Table 1 Distribution of HR HPV types in histologically normal and abnormal tissue
HR HPV infections
Study Histology No. of lesions H16 H18 H31 H33 H35 H39 H45 H51 H52 H56 H58 H59 H68 Subtotal
FHIT transcript study Normal 47 7 0 00100000100 9
Cervicitis 11 8 0 00444000000 2 0
CIN1 79 23 1 62200000110 3 4
CIN2 28 9 17 00000000000 2 6
CIN3 116 73 2 30200030510 8 9
Cancer 5 5 3 00000000000 8
Total 286 125 23 90944030720 1 8 6
FHIT protein study Normal 27 0 1 21000000000 4
Cervicitis 0 0 0 00000000000 0
CIN1 8 1 2 00000000000 3
CIN2 20 5 3 00000000200 1 0
CIN3 59 17 4 04000000000 2 5
Cancer 9 7 1 00000000000 8
Total 123 30 11 25000000200 5 0
FT
AbnT }
Figure 1 Agarose gel electrophoresis of semi-nested RT–PCR products
(lanes 1–9). Size markers in lane 10 are 200, 400, 600, 800, 1000, 1500,
2000, 2500, 3000, 4000, 5000, 6000, 8000 and 10000 bp from bottom up-
wards. FT=normally spliced transcript (702 bp). AbnT=abnormal tran-
scripts.
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PCR as described above. For histological and immunohisto-
chemical staining, sections were de-waxed with xylene and
stained with either haematoxylin and eosin or FHIT antibody
(Zymed). FHIT antibody was used at a dilution of 1/200 after
epitope retrieval in accordance with the manufacturer’s instruc-
tions and its presence detected by reaction with monoclonal
alkaline phosphatase conjugated anti-rabbit IgG antibody
(gamma chain speciﬁc) at a dilution of 1/100 (Sigma A2556)
and 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium
(Sigma B5655) as substrate. Nuclei were stained with 0.1%
nuclear fast red in 5% aluminium sulphate. Speciﬁc cytoplasmic
immunostaining for FHIT protein in cervical lesions was
assessed by comparison with normal epithelium (positive
control, present in most sections) and with stromal cells (nega-
tive control, present in all sections).
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Table 2 Distribution of HR HPV, abnormal FHIT transcripts (A) and abnormal FHIT protein expression (B) in histo-
logically normal and abnormal cervical epithelium
No. of lesions with abnormal FHIT transcripts
(A) Histology Total No. of HR HPV+ve lesions (%) Aberrant (%) None (%)
Normal 47 9 (19) 5 (11) 0
Cervicitis 11 8 (73) 2 (18) 0
CIN1 79 34 (43) 11 (14) 2 (3)
CIN2 28 26 (93) 6 (21) 0
CIN3 116 89 (77) 32 (28) 5 (4)
Total 281
No. of lesions with abnormal FHIT protein
(B) Histology Total No. of HR HPV+ve lesions (%) Reduced (%) Absent (%)
Normal 27 4 (15) 0 0
Cervicitis 0 0 0 0
CIN1 8 3 (37) 0 0
CIN2 20 10 (50) 3 (15) 0
CIN3 59 25 (42) 7 (12) 4 (7)
Total 114
Exons
Abnormal
transcripts
Abnormal
exon
boundaries
Normal
exon
boundaries
1
2
3
4
5
6
34 5 6 7 89 1 0 AB
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702bp
244bp
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337bp
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ATG TGA
FH904 FH1038
Figure 2 Abnormal FHIT transcripts found in this study and their generation by alternative splice site usage. Only the region ampliﬁed by the FH203S/
FH1038 primers is shown. The FHIT coding sequence start and stop codons are indicated and the origins of two abnormal exons found (grey) are labelled A
and B. Introns are shown on a 500 times smaller scale than exons. Numbering of the ﬁrst and last bases of exons is from Genbank accession number
NT_005607.3.
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The histological grades and the HR HPV status of the lesions used
in this study, subdivided into those used for FHIT transcript or
protein detection, are shown in Table 1. High grade lesions were
predominantly associated with HPV16, HPV18, HPV31, HPV33,
HPV35 and HPV58 but 20% (29 out of144) were negative for
HR HPV. Seven lesions contained more than one HR HPV type.
Cancer biopsies were included as positive controls for fully inva-
sive disease and one of these was HR HPV negative. The
association of high grade lesions with HR HPV was clearly evident
(Ptrend50.001 in the transcript study and Ptrend=0.012 in the
protein study).
Representative semi-nested FHIT transcript PCR products are
shown in Figure 1. Full length FHIT transcripts were not detectable
in nine lesions (two cancers, ﬁve CIN3 and two CIN1). Abnormal
splicing patterns similar to those previously reported (Sozzi et al,
1996) were found by nucleic acid sequencing to be responsible
for size-shifted PCR fragments. These included (i) skipping of
exons 4–8, exons 5–8, exons 5–6 with an alternative splice site
within exon 7 or exons 6–9 with alternative splice sites within
exons 5 and 10, (ii) replacement of exons 5–7 with 138 bases from
intron 5 and (iii) an insertion of a 50 base sequence from intron 7
between exons 7 and 8 (Figure 2). After adjusting for HR HPV,
abnormal FHIT transcript expression (aberrand and absent) was
found to be associated with increasing CIN grades (Ptrend50.001)
(Table 2A).
Figure 3 shows the FHIT protein staining criteria used in grad-
ing individual lesions. FHIT protein expression was readily
detectable in all normal epithelium and CIN1 lesions and in most
CIN2/3 lesions but was totally absent in four CIN3 lesions (Table
2B). One of these was associated with HPV18 but the remaining
three contained no detectable HR HPV. After adjusting for HR
HPV, abnormal FHIT protein expression (reduced or absent) was
also found to be associated with increasing CIN grade
(Ptrend=0.004).
DISCUSSION
A full length FHIT transcript was detected in all normal cervical
tissue samples and in all but 3% (7 out of 223) of CIN lesions
(Figure 1, Table 2A). The precise signiﬁcance of its detection in
almost all CIN lesions is unclear since it could have been derived
from abnormal and/or adjacent normal epithelium. The presence
of abnormal FHIT transcripts could be clearly identiﬁed and their
nature deﬁned by nucleic acid sequencing. They were found to be
generated by alternative splice site usage and cryptic alternative
splice sites were identiﬁed in exons 5, 7 and 10 and in introns 5
and 7 (Figure 2). Our results show that abnormal transcripts can
be found in both histologically normal and abnormal tissues (Table
2A).
When compared against stromal cells within the same section,
expression of FHIT protein in epithelial cells was found in all
normal tissues and low grade CIN1 as well as in most high grade
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Figure 3 Immunohistochemical staining with FHIT antibody. (A) Normal epithelium (positive control) 6100, (B) a positive CIN2 lesion6350, (C)a
positive CIN3 lesion showing microinvasion6350 and (D) a negative squamous cell carcinoma6350. Stromal cells present in all sections were used as
an internal negative control.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 376–381CIN2/3 lesions (Table 2B, Figure 3). This is to be expected if full
length FHIT transcripts are expressed in most CIN lesions (Figure
1, Table 2A). However, abnormal FHIT protein expression was
found in a proportion (17%) of exclusively CIN2 and CIN3 lesions
and interestingly, three of the four CIN3 lesions which showed no
FHIT protein expression also had no detectable HR HPV. Similar
abnormal FHIT protein expression has previously been found in
52% of high grade lesions associated with cancer but only in 8%
of those not associated with cancer (Connolly et al, 2000). This
suggests that these CIN2/3 lesions could carry an increased risk
of malignancy.
Recent evidence suggests that FHIT instability may play a syner-
gistic role with HR HPV in the pathogenesis of high grade cervical
lesions (Butler et al, 2000). HPV16 genomes have been found inte-
grated in the vicinity of the FHIT coding sequence and the
presence of HPV16 DNA was associated with LOH in the FHIT
region (Muller et al, 1998; Butler et al, 2000; Yoshino et al,
2000). Detailed typing of HR HPV in our study did not show
any associations between abnormal FHIT transcript expression
and presence of speciﬁc HR HPV types or all HR HPV taken
together. This is consistent with a negative correlation found
between the presence of HPV E6/E7 transcripts and abnormal
FHIT transcripts in cervical cancers (Segawa et al, 1999).
Our results indicate that, after adjusting for HR HPV, abnormal
FHIT transcript expression (Ptrend>50.001) or abnormal FHIT
protein expression (Ptrend>50.004) represents a risk factor for
the development of high grade CIN lesions. This suggests that
genomic instability at the FHIT locus induced by other risk factors
(e.g. cigarette smoking, alcohol consumption or concurrent chronic
inﬂammation) could account for the development of those high
grade cervical lesions which are HR HPV negative and which
may have a lower risk of cancer and tend to regress in the absence
of persistent HR-HPV infection. For clinical or epidemiological
purposes, testing for FHIT protein, rather than FHIT transcripts,
would have obvious advantages since it can be carried out using
low cost and simple procedures on routine parafﬁn sections.
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